Skip to Content

Portage Biotech Inc PRTG

Morningstar Rating
$1.35 +0.02 (1.50%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PRTG is trading at a 63% discount.
Price
$1.33
Fair Value
$2.84
Uncertainty
Extreme
1-Star Price
$84.96
5-Star Price
$3.82
Economic Moat
Xcb
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRTG is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.33
Day Range
$1.311.40
52-Week Range
$1.217.67
Bid/Ask
$1.33 / $1.35
Market Cap
$26.69 Mil
Volume/Avg
7,282 / 27,684

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
7

Valuation

Metric
PRTG
Price/Earnings (Normalized)
Price/Book Value
0.53
Price/Sales
Price/Cash Flow
Price/Earnings
PRTG

Financial Strength

Metric
PRTG
Quick Ratio
1.25
Current Ratio
2.00
Interest Coverage
−7,945.31
Quick Ratio
PRTG

Profitability

Metric
PRTG
Return on Assets (Normalized)
−6.83%
Return on Equity (Normalized)
−10.67%
Return on Invested Capital (Normalized)
−8.93%
Return on Assets
PRTG

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRJxzdn$456.5 Bil
VRTX
Vertex Pharmaceuticals IncJjzzbkj$91.4 Bil
REGN
Regeneron Pharmaceuticals IncLrkltq$89.8 Bil
SGEN
Seagen Inc Ordinary SharesFrnbyt$40.2 Bil
MRNA
Moderna IncRzg$29.6 Bil
ARGX
argenx SE ADRJfyd$26.4 Bil
BNTX
BioNTech SE ADRMtwt$23.9 Bil
ALNY
Alnylam Pharmaceuticals IncYrmlf$21.1 Bil
BMRN
Biomarin Pharmaceutical IncBmclxp$17.2 Bil
INCY
Incyte CorpPmrhhzh$12.2 Bil